Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells.
Megiorni F, Gravina GL, Camero S, Ceccarelli S, Del Fattore A, Desiderio V, Papaccio F, McDowell HP, Shukla R, Pizzuti A, Beirinckx F, Pujuguet P, Saniere L, der Aar EV, Maggio R, De Felice F, Marchese C, Dominici C, Tombolini V, Festuccia C, Marampon F.
Megiorni F, et al. Among authors: tombolini v.
J Hematol Oncol. 2017 Oct 6;10(1):161. doi: 10.1186/s13045-017-0530-z.
J Hematol Oncol. 2017.
PMID: 28985758
Free PMC article.